RLMD Earnings

RLMD reported its earnings on 2025-11-13, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was -0.3, surpassing the expected -0.04 by -650% . The stock experienced a 1.8% price change on the earnings day and a 7.73% change over the next five days, reflecting market reactions to the results.

Following RLMD's earnings announcement on 2025-11-13, the stock price moved by 1.80% on the day of the release. Over the subsequent five days, it saw a 7.73% change. Historically, RLMD's stock price tends to shift by an average of -1.31% in the 10 days leading up to earnings and +3.86% in the 10 days following, providing insight into potential market.

For , analysts estimate RLMD’s annual revenue to reach undefined, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -4.88% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between RLMD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -4.88%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RLMD's stock price typically moves by -1.31% in the 10 days before its earnings and +3.86% in the 10 days after. For the upcoming earnings, analysts expect an EPS of 0.00 and revenue of undefined.

The earnings call presents a mixed picture. Financial performance shows reduced losses and expenses, which is positive, but cash reserves are dwindling. Product development updates and strategic plans seem promising, but are contingent on future FDA approvals and trial outcomes, posing significant risks. The Q&A session reveals potential market opportunities but lacks clarity on pricing strategies and timelines. Overall, the sentiment is neutral, as the positive aspects are balanced by uncertainties and risks, particularly in regulatory and market adoption areas.